No association between the response to the addition of an atypical antipsychotic drug to an selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor and the brain-derived neurotrophic factor (Val66Met) polymorphism in refractory major depressive disorder in Japanese patients

Reiji Yoshimura, Taro Kishi, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Asuka Katsuki, Kenji Hayashi, Nakao Iwata, Jun Nakamura

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Objective: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in treatment-refractory depression. Methods: The study enrolled 64 patients meeting the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder who were treated with at least two courses of a single antidepressant, but who had Hamilton Depression Rating Scale (HAMD-17) scores ≥15 points that were reduced less than 50% over at least a 4-week treatment period. There were 24 males and 40 females (age range 27-68 years; mean±SD, 48±13 years). The patients' clinical improvement was evaluated using the HAMD-17. Patients with at least a 50% decrease in the HAMD-17 score were defined as responders. Serum BDNF levels were assayed using enzyme-linked immunosorbent assays and the presence of the BDNF (Val66Met) polymorphism was determined using the TaqMan genotyping assay. Results: No correlation was found between the BDNF (Val66Met) polymorphism and a positive response to adding an atypical antipsychotic drug. No differences were observed in the changes in the serum BDNF levels and HAMD-17 scores between Val66Val and Met-carriers. In addition, in patients who experienced remission, the atypical antipsychotic drug was discontinued after at least 3 months of treatment and the patients were then followed for 1 year; 14 of 27 patients (52%) relapsed within 1 year. Conclusion: These results suggest that the BDNF (Val66Met) polymorphism is not associated with the response to the augmentation of a SSRI or SNRI with an atypical antipsychotic drug, and that the combination of an atypical antipsychotic drug and a SSRI or SNRI should be continued for 3 months or more in refractory depressed patients in the Japanese population. Copyright

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalClinical Psychopharmacology and Neuroscience
Volume10
Issue number1
DOIs
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'No association between the response to the addition of an atypical antipsychotic drug to an selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor and the brain-derived neurotrophic factor (Val66Met) polymorphism in refractory major depressive disorder in Japanese patients'. Together they form a unique fingerprint.

Cite this